Pharma

Your Article Summary

See Latest Articles

Serono Announces Results From Pivotal Phase III Clinical Trial of Its Proprietary Recombinant Human Growth Hormone in the Treatment of HARS at the XVI International AIDS Conference
Corporate News Releases - The Healthcare Sales & Marketing Network, 08/18/06

Serono announced positive results of a pivotal Phase III trial of Serono's recombinant human growth hormone (r-hGH) for the treatment of HIV-associated Adipose Redistribution Syndrome (HARS) at the XVI International AIDS Conference in Toronto, Canada. Results of the trial were presented as a late-breaker session on August 17th during the International AIDS Conference

Today in Drug Trials...keeping you current

Receive free subspecialty "5-minute updates" via email

Antithrombotic therapy and outcomes of patients with atrial fibrillation following primary percutaneous coronary intervention: results from the APEX-AMI trial
European Heart Journal, 06/09/09

Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841
Journal of Clinical Oncology, 06/15/09

Rationale, design, and baseline characteristics of the Acetylcystein for Contrast-Induced nephropaThy (ACT) Trial: a pragmatic randomized controlled trial to evaluate the efficacy of acetylcysteine for the prevention of contrast-induced nephropathy
Trials, 06/05/09

See All of Drug Trials